Research Analysts Set Expectations for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($4.17) per share for the year, up from their previous forecast of ($4.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

A number of other brokerages also recently issued reports on JSPR. Royal Bank of Canada lowered their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price for the company. HC Wainwright cut their target price on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price for the company. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $64.44.

Jasper Therapeutics Trading Up 2.7 %

JSPR opened at $5.68 on Thursday. The stock has a market cap of $85.21 million, a PE ratio of -1.20 and a beta of 2.11. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The stock’s fifty day simple moving average is $8.99 and its 200 day simple moving average is $16.56.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35).

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets grew its position in shares of Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares in the last quarter. Wells Fargo & Company MN grew its position in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares during the last quarter. EntryPoint Capital LLC bought a new position in Jasper Therapeutics during the 4th quarter worth approximately $223,000. Finally, Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics during the third quarter valued at about $251,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.